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Abstract
Health equity in pharmaceutical research is concerned with creating equal opportunities for men and women to
partake in clinical trials. Equitable representation is imperative for determining the safety, effectiveness, and
tolerance of drugs for all consumers. Historically, women have been excluded from participating in clinical research
leading to a lack of knowledge regarding drug effects and their consequences. This paper examines the changes
made since the implementation of Canadian policies on the representation of women in clinical trials, the analysis
of sex and gender, as well as the discourses that are prominent among researchers. A feminist ethics framework is
used to examine the structures that endeavor to elucidate women’s involvement in trials, as experienced under
extensive patriarchal history. Scholarly literature and Canadian government policy documents are used to explore
the development of clinical trials as pertaining to sex and gender. Findings suggest that women continue to be
underrepresented or excluded from important research, highlighting ongoing ethical and justice concerns.
Improvement recommendations for policies are outlined.
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Introduction
Health equity is concerned with the attainment of equal
opportunities for good health and high quality health care
for all people [1]. It requires continuous efforts on behalf
of society to address historical and contemporary injus-
tices pertaining to the resources necessary for health in-
cluding, access to quality healthcare, and safe living and
working conditions. When it comes to pharmaceuticals,
health equity is concerned with fair rights for all individ-
uals, to the access and participation in clinical research so
that the safety, effectiveness, and tolerance of drugs can be
determined. This paper seeks to explore the changes made
since the implementation of Canadian policies on the rep-
resentation of women in clinical trials, the analysis of sex
and gender, as well as the discourses that are prominent
among researchers. In order to do so, this paper will
review Health Canada’s policy: Guidance Document on the
Inclusion of Women in Clinical Trials (1997) and its revi-
sion in 2013, the Health Portfolio Sex and Gender-Based
Analysis Policy (2009) and its revision in 2012, as well as
the literature of existing research. A feminist ethics frame-
work will be used to highlight the structures that endeavor
to elucidate women’s involvement in trials, as experienced
under extensive patriarchal history.
Biological sex differences
Proper generalizations of drug outcomes to both men and
women require researchers to consider the biological dif-
ferences between the sexes. Pharmacokinetic and pharma-
codynamic differences stem from variations in body size,
composition, and hormones. Women’s smaller body sizes
and higher fat contents typically result in varied drug re-
sponses [2]. A study conducted by Ridker et al. [3] showed
that aspirin has differential effects on the sexes with
regard to primary protection against strokes and heart at-
tacks. As oppose to men, Aspirin only lowered women’s
risk of stroke but had no effect on the risk of myocardial
infarction or death. In another study, the liver enzyme CY
P3A4 showed a slowed drug clearance rate in women
when compared to men, resulting in decreased effective-
ness of antidepressants, anxiolytics, painkillers and
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anticonvulsive drugs [4]. In reference to hormonal varia-
tions, fluctuating levels of estradiol and progesterone dur-
ing the female menstrual cycle, drastic increases in
hormones during pregnancy, and changes in metabolism
as a result of contraceptives, all affect the pharmacokinet-
ics and pharmacodynamics of drugs prescribed [2]. As
such, it is evident that in order for women to make in-
formed decisions with respect to their health, drug out-
comes must be thoroughly evaluated in both sexes so that
comprehensive information about safety, and effectiveness
can be made publically available.
Gender-based differences
In addition to biological variations in sex, gender-based
differences must be reflected as they likewise account
for variations in drug outcomes. The concept of gender,
is broadly used to refer to gender roles, in which women
and men are expected to behave in certain ways in soci-
ety. This social construction of gender norms has
important implications for women’s health. Epidemiolog-
ically, certain medical conditions are unique to women,
while others are more prevalent, reflecting the differ-
ences in women’s experiences [5]. For example, women
are twice more likely to experience depression at some
point in life when compared to men [6]. This has been
attributed to the unique experiences of women such as
postpartum depression, menopause and the additional
stresses of dual work days consisting of paid employ-
ment, and unpaid domestic labour (household chores
and caregiving for children and elderly). Unfortunately,
even when women are included in clinical trials, re-
searchers often fail to determine whether the gender of
the study subject affected the outcomes [5].
On the whole, researchers must account for both bio-
logical and gender-based differences in their findings in
order to properly attribute drug responses. Crucial fac-
tors to consider are women’s higher life expectancies
leaving them prone to chronic diseases requiring the
prolonged use of medications. As such, drugs pertaining
to all diseases and conditions experienced by women
should be evaluated in clinical trials and generalized ap-
propriately in order to protect and sustain women’s
health.
Historical context
The history of women’s participation in clinical trials is re-
corded through policies and regulations. “Policy develop-
ment in the area of protection of human research subjects
began in 1949 with the issuance of the Nuremberg Code,
which outlined standards for the judgment of flagrantly
abusive human experimentation conducted by the Nazis
during World War II” ([7]: p2). This document as well as
the related declaration of Helsinski (1964) formed the
basis for Health Canada and US research regulations. In
the mid-1900s, health problems caused by the drugs thal-
idomide and Diethylstilbestrol (DES), signified abuse and
brought about a public awareness for the need for greater
protection for fetuses from hazards in medicine. Thalido-
mide was used by pregnant women in Canada from 1959
to 1962, to prevent morning sickness and was later found
to cause peripheral neuritis and severely malformed limbs
in newborns [7].
In 1938, DES, a synthetic hormone prescribed to an
estimated 200,000 to 400,000 Canadian women to pre-
vent miscarriages, was found 30 years later to have
harmful effects on their daughters; reducing fertility and
causing adenocarcinoma of the vagina [8]. Following the
thalidomide and DES disasters, protective regulations di-
rected towards women of childbearing years became im-
plemented. In the late 1970s, the US Food and Drug
Administration (FDA) adopted a policy of exclusion en-
titled “General Considerations for the Clinical Evaluation
of Drugs,” recommending that premenopausal women
capable of becoming pregnant be excluded from partici-
pating in Phase I and early Phase II of drug trials [9].
Thereby, banning all women from the age of puberty to
menopause from pharmaceutical research in order to
avoid any likelihood of causing fetal harm. While this
policy was supposed to refer only to women of child-
bearing years and early phases of clinical trials, it quickly
translated to all women being excluded from all pharma-
ceutical research for almost two decades [10].
The lack of information regarding the safety and effec-
tives of pharmaceuticals that were never tested on women
led to a strained relationship between physicians and their
female patients. Physicians were reluctant to prescribe
medications, diagnosed women later or provided them
with less aggressive treatments when compared to men
[7]. Findings on heart disease demonstrated that women
may be diagnosed later than men, and be less likely to be
offered invasive procedures such as coronary angioplasty
or coronary artery bypass surgery [11]. In addition, lower
case survival rates have been observed in women follow-
ing diagnosis of Acquired Immunodeficiency Syndrome
(AIDS), reflecting later identification and less aggressive
treatment [11]. Finally, women with kidney disease had
difficulty gaining access to dialysis and transplantation,
and were later diagnosed with lung cancer and heart dis-
ease, resulting in morbidity and mortality [7].
In the 1980s, AIDS activists working to endorse access
to experimental therapies presented the first formal
challenge to the protectionist policies of the prior de-
cades [11]. They were successful in receiving access to
trials utilizing experimental AIDS drugs for the treat-
ment of the serious and life-threatening illness. From
then on, women’s advocacy continued with the recogni-
tion that clinical outcomes of medications must be eval-
uated on both sexes.
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Concerns over the lack of research on breast and re-
productive cancers amplified lobbying for the inclusion
of women in clinical trials and in 1997 led to the devel-
opment of the Canadian Guidance Document on the In-
clusion of Women in Clinical Trials [10]. The policy
served as Health Canada’s promise to develop and apply
Gender-Based Analysis (GBA) to programs and policies
in order to address the differential needs of men and
women. The Guidance Document: Considerations for In-
clusion of Women in Clinical Trials and Analysis of Sex
Differences, was released in 2013 to supersede the 1997
version.
In addition, in the year 2000, Health Canada unveiled
another strategy to support a GBA in a document enti-
tled Health Canada’s Gender-Based Analysis Policy
(GBAP) [8]. The purpose of this reform was to address
health differences between men and women as they per-
tained to sex and gender, understand experiences with
health and illness and the interaction with the health
care system. Its goals were to be accomplished by “iden-
tifying gender equality issues and proposing remedies to
inequality in the areas of policy and program develop-
ment or implementation, research, funding, data collec-
tion, surveillance, and regulatory activities” ([8]: p.10). In
2009, the Health Portfolio Sex and Gender-Based Ana-
lysis Policy replaced the former document. Finally, in
2012, the term “gender-based analysis” was modified to
“gender-based analysis plus,” highlighting a new approach
which takes into account the intersectional nature of
women’s identities and considers factors such as age, edu-
cation, income, language, geography, and culture [12].
Methodology/methods
This paper will utilize a feminist ethics theoretical lens
to examine the structures that endeavour to elucidate
women’s underrepresentation in clinical research, as ex-
perienced under extensive patriarchal history. Feminist
ethics is an approach to ethics that builds on the notion
that traditional ethics have failed to appreciate and value
women’s moral experience [13]. Feminists apply a
gender-centered approach to ethics in order to rethink
and examine issues pertaining to how notions of sex and
gender limit and restrict women. By highlighting that so-
ciety is male-centered, feminists can expose practices of
androcentric reasoning in the justification for excluding
women from participation in clinical research [14].
Ethical questions concerning policies on the inclusion
of women in clinical research seek to determine whose
interests are served, and how the policy will affect gen-
der oppression. Feminist ethics scholars are focused on
analyzing why women are unjustly excluded or under-
represented and in turn suffer adverse health conse-
quences, how research agendas and decisions are
formulated and what discourses continue to promote
oppressive practices [15].
Furthermore, the feminist ethics framework appeals to
social justice theory that emphasizes the rationales that
steer injustices, which privilege some people and harm
others through the uneven distribution of power in our
society. Social justice seeks to understand processes that
underpin injustices and challenge them to promote
equity and autonomy [15]. It recognizes that oppression
on the basis of gender translates into injustices in the
form of marginalization and leads to inequitable health
care for women. Thus, when it comes to clinical re-
search policies, feminist ethics and social injustice con-
ceptions investigate how their implementation will affect
current practices of power and oppression.
On the whole, by applying a gendered lens, feminist
ethics seeks to analyze the norms and assumptions that
govern clinical trials in a perspective that allows us to
understand how research practices involving and affect-
ing women have undervalued and harmed them. Ques-
tions such as whose interests are served and whose are
harmed, must be considered in order to highlight the
ways in which research has served the interests of privi-
leged social groups and oppressed the marginalized [16].
Thus, in using the feminist ethics framework and ap-
pealing to social justice theory we can better recognize
the changes that need to be institutionalized if the con-
duct of clinical research is to meet standards of health
equity for women.
Scholarly literature and Canadian government policy
documents were used by the author to explore the de-
velopment of clinical trials as pertaining to sex and gen-
der. Policy documents were taken from Canadian
government websites, and scholarly research used to cri-
tique the reforms were found through Google Scholar,
and databases such as Pubmed.
Results
Feminist ethics, social justice and societal norms
Dating back to the third century BC, the great Greek
philosopher Aristotle believed that women were imper-
fect men as they did not reproduce semen and that the
female nature should be viewed as afflicted with natural
faultiness [17]. Aristotle’s central notion concerning
women is that they are by nature mediocre to men and
must therefore be subordinate to, and ruled by them. In
the early twentieth century, Simone de Beauvoir has had
significant influence on feminist ethics by explaining the
Hegelian concept of the Other which refers to what is
unfamiliar and deviating from the norm [18]. Her book
The Second Sex, views this socially constructed concept
as the foundation of women’s oppression in the
male-dominated culture. It places the male as standard
or the norm in society in relation to women who are the
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other or minority. The process of othering is a type of
oppression which is endorsed by those who have know-
ledge, and power and use this to achieve a particular
political agenda in its goal of domination [19].
Stemming from this concept of othering, Susan Sher-
win a contemporary feminist ethics scholar appeals to
Iris Young’s social justice theory which identifies oppres-
sion as a form of injustice. Young’s notion of social just-
ice recognizes that oppression on the basis of gender
translates into injustices in the form of marginalization
and leads to unjust health care [15]. Thus, when it
comes to clinical trials, feminist ethics and social injust-
ice conceptions of power and oppression, enable a more
comprehensive understanding of current research prac-
tices which are governed by androcentric reasoning and
domination and lead to inequitable health outcomes for
women.
Policies and clinical trials
Guidelines and recommendations for the inclusion of
women in clinical trials were developed in response to
alarms stressing that harms and injustices were being
done to women from consuming drugs for which they
have not been tested for [10]. In 1997, the Guidance Docu-
ment on the Inclusion of Women in Clinical Trials was an-
nounced by Canadian minister Alan Rock [20]. It
recommended that women should be included in all
phases of clinical trials in an appropriate sample size that
would allow for adequate effects of drug treatments to be
evaluated. This in turn, would lead to safer prescriptions
and decreased adverse health consequences. Inclusion cri-
teria were directed to all females of childbearing and
post-menopausal years, and researchers were encouraged
to include women as well as to analyze outcomes of treat-
ments by sex-related differences. In addition, drug manu-
factures were to safeguard that those drugs seeking
market approval included women at all stages of the drug
development process to ensure that the full spectrum of
risks and benefits were captured throughout the clinical
trial. The Committee on the Elimination of Discrimination
Against Women, applauded the health ministry with the
development of these guidelines stating that it was an im-
portant step towards recognizing that women experienced
more chronic health conditions, and consumed more
medication. Thus, their safety must be acknowledged [21].
In review of the Canadian policy, Canadian guidelines
served merely as recommendations for drug manufac-
turer with no mandatory pre-requisite to conform [10].
The Women’s Health Strategy of Canada [10] promised
to monitor the inclusion of women in clinical trials but
this was never mandated or put into practice. The Tri
Council Policy on the ethical conduct of research involv-
ing humans simply stated that, “Women shall not auto-
matically be excluded from research solely on the basis
of sex or reproductive capacity,” with no other mention
of how this was to be enforced [22].
Guidelines from the National Institutes of Health
(NIH) in the US made it a requirement for researchers
to include women in clinical trials if they were to be
funded [10]. As a follow-up, various investigators includ-
ing the General Accounting Office in the US assessed
the inclusion of women in clinical trials since the imple-
mentation of these policies but found their continued
underrepresentation in research [10]. Considering that
the NIH, having an actual requirement for inclusion
failed to bring about change, it is not surprising that in
Canada, guidelines that served simply as recommenda-
tions, were unsuccessful. In actuality, neither the US or
Canada had policies that enforced monitoring provisions
for the new guidelines.
In March of 2013, Health Canada released its updated
version of the Guidance Document for Considerations for
Inclusion of Women in Clinical Trials and Analysis of
Sex [23]. The document acknowledged that since the
1990s women’s participation in clinical research has in-
creased but underrepresentation continued to be evident
especially in the early phases of trials. Furthermore,
pregnant and breastfeeding women continued to be ex-
cluded leading to gaps in knowledge and safety concerns
about the effects of treatments.
The amendments in the 2013 document meant to pro-
vide advice to researchers regarding the analysis of sex
differences in efficacy of therapies, as well as guidance
for inadvertent pregnancy and inclusion of pregnant/
breastfeeding women. More specifically, researchers
were to carefully plan the design of the trials so that sex
differences can be analyzed in a meaningful way, and to
provide rationale for any variations in drug responses.
Consent forms and counselling were to be offered to all
pregnant women regarding potential fetal and repro-
ductive risks. Well understood procedures had to be in
place in case inadvertent pregnancy does occur during a
clinical trial [23]. Nevertheless, as with the 1997 docu-
ment, the 2013 guidelines continue to serve merely as
recommendations to drug sponsors. To-date, it is still
not mandatory to include women and there is no clear
indication as to how or if monitoring provisions will ever
be enforced.
Literature suggests that while there is no official moni-
toring for the inclusion of women in research in Canada,
it is expected that the enrolment practices are similar to
those in the United States [24]. Reports from The Food
and Drug Administration (FDA) demonstrate that while
women’s participation in clinical trials has progressively
improved from < 20% in the 1990s to over 45% between
2010 and 2012, the inclusion in certain cardiovascular
and cancer trials remains problematic (24,25). A recent
study conducted by Pilote (24) shed light on the
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underrepresentation of women (24%) in ischemic heart
disease (IHD) and heart failure trials, the most common
cardiovascular conditions affecting women in the general
population. In addition, studies explicitly exclude elderly
females from drugs for IHD, even though the disease is
more prevalent in older age [25]. Another study looking
at the representation of women in Oncology trials from
2003 to 2016, highlighted the continual shortage of fe-
male patients’ in trials for melanoma (35%), lung (39%),
and pancreatic (40%) cancers [26].
The routine exclusion of pregnant women remains a
concern [27]. A recent study concluded that out of 558
Phase IV trials, only five (1%), were designed purposely
for pregnant women. The findings also demonstrated
that 95% of qualified studies overtly excluded pregnant
women, signifying this to be a common practice. As
such, this study serves as evidence that industry is not
conducting research on pregnant women and highlights
the importance of the need for change in practice. In
addition, despite the fact that during pregnancy two to
three out of five women use four or five medications,
there are only a few drugs that are labelled for-use dur-
ing pregnancy [27]. Data on dosage and safety for most
medications on the market remains insufficient. A 2011
study of all therapeutic agents approved by the FDA
from 1980 to 2010, found that 91% of these medications
did not have sufficient information for their use and
risks when taken during pregnancy [28].
In light of these findings, a mandatory shift towards a
justification model for excluding pregnant women from
important clinical research is recommended. In other
words, pregnant women should be included in research
unless there is reasonable justification that the tested drug
will produce harm to either the mother or the fetus [29].
In review of the GBAP there is no mention that gen-
der and sex-based differences must be analyzed separ-
ately for their impact on the experiences of women
taking medication. A study conducted at the University
of British Columbia’s Centre for Health Services and
Policy Research found that GBAP was neither adopted
nor implemented in pharmaceutical policy and lacked
translation into research practices [30]. Likewise, Doull
et al. [31], investigated the use of GBA in 38 Cochrane
systematic reviews of cardiovascular health, finding that
GBA was largely lacking in the examined literature.
Most commonly, if sex or gender were mentioned, the
terms were used interchangeably and there was no men-
tion of the intersectional nature of women’s identities
[31]. More recently, a study examined the reporting of
sex and gender in randomized controlled trials (RCT)
across Canada during the period of January 2013–July
2014. The results demonstrated poor analysis of sex and
gender, and no analysis of the intersectional nature of
women’s identities, in any of the reviewed research [32].
Discourses among researchers
The Canadian Research Ethics Boards (REBs) examiners
reviewed the various assumptions or rationales re-
searchers voice as justification for the underrepresenta-
tion or exclusion of women in their clinical trials [33].
Some researchers believe that women are in essence like
men in terms of biological similarities and thus finding
can be generalized to them. Yet, others acknowledge the
biological differences and argue that women introduce
too much variation into the data, complicating the re-
sults and making interpretation difficult. Thus, it is eas-
ier and simpler to study only male participants.
A number of researchers denote that as a result of
possible harmful effects from early phases of trials,
women are fortunate to avoid participation. However,
more often than not, participants do receive favourable
outcomes if proper guidelines and safety precautions are
followed. They also experience better attendant care and
benefit psychologically regardless of being issued the real
treatment or a placebo.
As women have traditionally been excluded in trials
some researchers inadvertently continue the trend with-
out pondering the consequences or simply state, that
women will be included in future research. Difficulties in
recruiting and retaining women and expenses that arise
due to retention failure, are also rationales for underrep-
resentation or exclusion. When it comes to enrolling
pregnant women, researchers continue to fear harming
embryos or fetuses and especially the associated legal li-
ability [33]. It is also a matter of ease as “pregnant
women are the only population for which justification
for exclusion does not need to be given, making it easy
for investigators to avoid issues entirely” ([34]: p.5).
Discussion
This paper examined the representation of women in
clinical trials and the analysis in research by sex and
gender. Findings from various studies demonstrate that
women continue to be underrepresented in clinical re-
search even if conditions such as cardiovascular disease,
and certain cancers are more prevalent to them in soci-
ety. Significant underrepresentation is noted for elderly
women and those who are pregnant are often routinely
excluded. While the overall representation of women in
clinical trials has improved, the analysis of research re-
sults by sex, gender and the intersectional nature of
women’s identities remains poor.
When the REBs reviewers investigated the causes for un-
derrepresentation and exclusion they found common ratio-
nales for the justification of these practices. As such,
literature suggests that shared cultural biases continue to
dominate medical research and unethical and oppressive
practices are still present. In relation to the feminist ethics
framework, Simone de Beauvoir’s socially constructed
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concept of women as the other is seen through the contin-
ued male standard and dominance of male subjects in clin-
ical trials. Results from research looking at the effects of
pharmaceuticals from studies where more men are sam-
pled, are generalized to women with little consideration for
differences in sex or gender.
The feminist ethics framework enables us to recognize
that andrecentricity continues to demote women’s expe-
riences to a position deviating from the norm and in
turn, causes adverse effects to women’s health and well-
being. According to Susan Sherwin [15], studies often
choose to select male subjects, as it is anticipated that
women will respond differently and distort the data.
Consequently, leaving the practitioner with inadequate
knowledge for the treatment of their female patients
[35]. In addition, due to the lack of knowledge regarding
therapeutic agents, women often choose to avoid taking
medications all together. In turn, putting themselves and
their fetus at risk for harmful effects.
Appealing to social justice, oppression in society on
the basis of gender is still very much present. The pass-
ing of the 1997 policy was in theory meant to improve
the oppressed status of women from being marginalized
to being included in clinical trials. Unfortunately, the un-
even sampling of sexes in trials continues to privilege
men, highlighting the ongoing unequal distribution of
power in our society. As such, it is likely that society’s
existing social structures based on male dominance and
power have initially stalled the federal government policy
from mandating stricter guidelines with enforced provi-
sions that ensure and demand the inclusion of all
women in clinical trials. In addition, androcentric struc-
tures are the root cause for why researchers themselves
have been intuitively less inclined to embrace more in-
clusive practices.
Upon the release of the 2012, revised draft version of
the guidance document: Draft Guidance Document:
Considerations for Inclusion of Women in Clinical Trials
and Analysis of Sex Differences [36], Health Canada
sought comments and suggestions for amendments from
agencies or the public. The Canadian Women’s Health
Network (CWHN), welcomed the opportunity to pro-
vide recommendations on the changes [37]. They noted
that the document continues to serve simply as a guid-
ance vs. a regulation and thus adherence is understood
as being optional. Since Women’s inclusion in clinical
trials is imperative, strict monitoring and penalties for
non- compliance should be in place. In situations where
it is not appropriate to include women in a trial, the
document should clearly outline the reasons appropriate
for exclusion. Finally, since the terms sex and gender
continue to be used interchangeably, there is a need to
further educate researchers on how to analyze results
accordingly.
The Canadian Alliance for Safe and Effective Use of
Medication in Pregnancy, also provided feedback and
recommended that the document establish two policies:
“one for drugs intended for both male and female con-
sumption and another for drugs intended for women
only” ([38]: p.16). In review of the 2013 final version of
the document, neither the changes from CWHN nor
The Canadian Alliance for Safe and Effective Use of
Medication in Pregnancy, were implemented. They con-
tinue to be important and should be re-addressed by
Health Canada in future revisions.
Recommendations for the GBAP are similar to the guid-
ance policy document. GBA should be mandated in
pharmaceutical research with appropriate monitoring.
Studies should analyze sex and gender separately for their
impact on drug outcomes. Annual reports should be made
available to the public in order for both women and men
to make informed decisions on the consumption of medi-
cation. Finally, researchers should be educated on how to
implement the policy in their studies [10].
Conclusion
There are general guidelines from Health Canada recom-
mending for women to be included in clinical trials as well
as a federal government commitment to the application of
GBA to research practices. However, at this time these
policies are not being sufficiently or properly imple-
mented. Women continue to be underrepresented or ex-
cluded from important clinical research resulting in a lack
of information regarding vital health outcomes. This lack
of clinical data and knowledge regarding prescribed drugs
is of concern to feminist ethics. In order to eradicate op-
pression in clinical trials and step back from othering
women in research we must first challenge existing social
structures of power and dominance by addressing and
reframing policies and study agendas. In practice, the in-
clusion of women in research advances commitment to
ethics and justice, and improves the applicability of re-
search findings where the ultimate goal is to ensure equit-
able health outcomes for both women and men.
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